Delving into the Latest Updates on Hebei Phoenix with Synapse

Overview

Tags

Immune System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

HLA-DR(HLA-DR antigens)	1

1.主要目的：评价注射用FNS007在RA受试者中多次给药的安全性和耐受性评价注射用FNS007在RA受试者中多次给药的药代动力学特征 2.次要目的评价注射用FNS007在RA受试者中多次给药的初步疗效评价注射用FNS007在RA受试者中的PK/PD特征评价注射用FNS007在RA受试者中的免疫原性

[Translation]

1. Primary objectives: To evaluate the safety and tolerability of multiple administrations of FNS007 for injection in RA subjects To evaluate the pharmacokinetic characteristics of multiple administrations of FNS007 for injection in RA subjects 2. Secondary objectives To evaluate the preliminary efficacy of multiple administrations of FNS007 for injection in RA subjects To evaluate the PK/PD characteristics of FNS007 for injection in RA subjects To evaluate the immunogenicity of FNS007 for injection in RA subjects

Start Date09 Nov 2021

Sponsor / Collaborator

Hebei Phoenix

CTR20190807 / CompletedPhase 1

注射用FNS007在健康受试者中单次给药的安全性、耐受性、药代动力学研究

[Translation] Safety, tolerability and pharmacokinetics of single-dose FNS007 for injection in healthy subjects

评价河北菲尼斯生物技术有限公司的注射用FNS007在中国健康受试者中单次给药的安全性、耐受性、药代动力学特征，为后续临床试验方案设计提供依据。

[Translation]

To evaluate the safety, tolerability, and pharmacokinetic characteristics of a single dose of FNS007 for injection developed by Hebei Phoenix Biotechnology Co., Ltd. in healthy Chinese subjects, and to provide a basis for the design of subsequent clinical trial protocols.

Start Date13 Aug 2019

Sponsor / Collaborator

Hebei Phoenix

100 Clinical Results associated with Hebei Phoenix

Login to view more data

0 Patents (Medical) associated with Hebei Phoenix

Login to view more data

2

Literatures (Medical) associated with Hebei Phoenix

25 Sep 2022·Sheng wu gong cheng xue bao = Chinese journal of biotechnology

[Advances of modified IL-2 molecules in drug development].

Article

Author: Ma, Xiaohan ; Huang, Lijing ; Wang, Hongquan ; Li, Chenhui

Interleukin-2 (IL-2) is one of the most important regulators in immune system, as it plays an essential part both in immune activation and suppression. However, as the first immunotherapy drug approved for the treatment of cancer, IL-2 is limited in clinical application by the serious adverse reactions. The long-felt needs in clinical practice, including prolonged half-lives, T cell subset specificity, and toxicity reduction can be achieved by polyethylene glycol (PEG) modification, Fc fusing, or protein mutation of IL-2. NKTR-214, the most advanced IL-2 pathway-targeted agent in clinical development for oncology, shows exciting results in treatment of melanoma in combination with nivolumab. At the same time, many more other modified molecules against cancer and autoimmune diseases are being tested in clinical research, an exciting future lying ahead for IL-2 therapeutics.

Zhongguo Yaoshi (Beijing, China)

Construction and Operation of Quality Management System in the Whole Process of Drug Research and Development

Author: Liu Chao ; Shi Jiangtao ; Cheng Ying ; Huang Lijing ; Wang Fei

Objective: To provide suggestions for the construction and operation of the quality management system of drug R & D laboratories, to assist R & D work in a standardized and scientific way and to improve the quality and efficiency of R & D.Methods: In this paper, the regulatory requirements related to drug R &D were combed, the role and current situation of the establishment of quality management system of drug R &D were briefly introduced, the management elements of the whole process of drug R & D were emphatically elaborated, and the similarities and differences of each laboratory were analyzed.Results and Conclusion: In quality management system of the whole process of drug R & D, risk assessment and control should run through the whole process, all laboratories should fully understand, standardize and effectively implement relevant management elements and continuously improve them so as to ensure the safety, effectiveness and quality control of researching and developing drugs.

100 Deals associated with Hebei Phoenix

Login to view more data

100 Translational Medicine associated with Hebei Phoenix

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

2

Other

Login to view more data